Drug · CHEMBL1773

CAPECITABINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. CAPECITABINE. Drugs and targets, record CHEMBL1773. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1773

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: CAPECITABINE; ChEMBL
ChEMBL ID: CHEMBL1773; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Capecitabine accord, Capecitabine component of xeliri capecitibine, Capecitabine component of xelox, Capecitabine medac, Capecitabine sun, Capecitabine teva, Ecansya (previously capecitabine krka), Xeloda; ChEMBL
Other names: Capecitabina, Capecitabine accord, Capecitabine medac, Capecitabine sun, Capecitabine teva, Capecitibine, Capecytabine, Capiibine, Captabin, Ecansya, NSC-759853, RO 09-1978/000, RO-09-1978000, RO-091978000, Ro-09-1978-000; ChEMBL
DrugBank: DB01101; DrugBank
InChIKey: GAGWJHPBXLXJQN-UORFTKCHSA-N; ChEMBL
Open Targets' highest stage: Approval, for 8 of its 139 diseases, from ATC, ClinicalTrials.gov, DailyMed, EMA Human Drugs and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
TYMS	Thymidylate synthase	Thymidylate synthase inhibitor	INHIBITOR	https://conductscience.org/library/genes/7298

Source ChEMBL

Diseases139

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
breast cancer	Approval	ClinicalTrials.gov and DailyMed	406	404	https://conductscience.org/library/drugs?q=MONDO_0007254
colorectal cancer	Approval	TTD	342	341	https://conductscience.org/library/drugs?q=MONDO_0005575
rectal cancer	Phase 3	ClinicalTrials.gov	264	264	https://conductscience.org/library/drugs?q=MONDO_0006519
gastric cancer	Phase 3	ClinicalTrials.gov	188	188	https://conductscience.org/library/drugs?q=MONDO_0001056
gastric adenocarcinoma	Phase 3	ClinicalTrials.gov	148	148	https://conductscience.org/library/drugs?q=MONDO_0005036
gastroesophageal junction adenocarcinoma	Phase 3	ClinicalTrials.gov	124	124	https://conductscience.org/library/drugs?q=MONDO_0003219
exocrine pancreatic carcinoma	Phase 3	ClinicalTrials.gov	62	62	https://conductscience.org/library/drugs?q=MONDO_0005192
malignant colon neoplasm	Phase 3	ClinicalTrials.gov	57	57	https://conductscience.org/library/drugs?q=MONDO_0021063
nasopharyngeal carcinoma	Phase 3	ClinicalTrials.gov	55	55	https://conductscience.org/library/drugs?q=MONDO_0015459
rectum adenocarcinoma	Phase 3	ClinicalTrials.gov	47	47	https://conductscience.org/library/drugs?q=MONDO_0002169

1 to 10 of 139Source Open Targets

See all 139 diseases

Trials2,080

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 5 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 46 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00112918	Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer	Phase 3	3,451	2012-09-06	capecitabine	Its name	ClinicalTrials.gov
NCT00089479	A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer	Phase 3	2,611	2011-06-23	capecitabine	Its name	ClinicalTrials.gov
NCT00069095	A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer	Phase 3	2,035	2016-01-22	capecitabine	Its name	ClinicalTrials.gov
NCT02872116	Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	Phase 3	2,031	2022-06-28	capecitabine	Its name	ClinicalTrials.gov
NCT00009737	A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer	Phase 3	1,987	2016-06-22	capecitabine	Its name	ClinicalTrials.gov
NCT00069121	A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer	Phase 3	1,886	2011-07-29	capecitabine	Its name	ClinicalTrials.gov
NCT03675737	Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)	Phase 3	1,579	2023-10-12	capecitabine	Its name	ClinicalTrials.gov
NCT00129935	EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer	Phase 3	1,384	2019-10-25	capecitabine	Its name	ClinicalTrials.gov
NCT00337103	E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	Phase 3	1,276	2013-09-30	capecitabine	Its name	ClinicalTrials.gov
NCT00082433	Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer	Phase 3	1,221	2009-08-17	capecitabine	Its name	ClinicalTrials.gov

1 to 10 of 2,080

See all 2,080 trials

Comparisons in its trials263

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AC Then T vs AC Then XT: serious adverse events	264 of 1,305	200 of 1,283	2,588	NCT00089479	Trial comparisons
Capecitabine vs 5-Fluorouracil + Leucovorin: Relapse-Free Survival	677 of 1,004	621 of 983	1,987	NCT00009737	Trial comparisons
Capecitabine vs 5-Fluorouracil + Leucovorin: Disease-free Survival	656 of 1,004	603 of 983	1,987	NCT00009737	Trial comparisons
Capecitabine vs 5-Fluorouracil + Leucovorin: Overall Survival	804 of 1,004	756 of 983	1,987	NCT00009737	Trial comparisons
Capecitabine vs 5-Fluorouracil + Leucovorin: serious adverse events	181 of 995	182 of 974	1,969	NCT00009737	Trial comparisons
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)	267 of 785	206 of 787	1,572	NCT03675737	Trial comparisons
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Experienced an Adverse Event (AE)	776 of 785	771 of 787	1,572	NCT03675737	Trial comparisons
Arm A: EC-T vs Arm B: ET-X: Number of Participants With Disease-free Survival (DFS) Event	127 of 669	170 of 715	1,384	NCT00129935	Trial comparisons
Arm A: EC-T vs Arm B: ET-X: deaths from any cause	70 of 669	83 of 715	1,384	NCT00129935	Trial comparisons
Arm A: EC-T vs Arm B: ET-X: Number of Participants With Overall Survival (OS) Event	70 of 669	83 of 715	1,384	NCT00129935	Trial comparisons

1 to 10 of 263

See all 263 comparisons in its trials

Papers from its trials1,086

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41324998	RESULT	1	PubMed
41202501	RESULT	1	PubMed
40739424	RESULT	1	PubMed
40448579	RESULT	1	PubMed
40025394	RESULT	1	PubMed
39972105	RESULT	1	PubMed
39282917	RESULT	1	PubMed
39036382	RESULT	1	PubMed
39035212	RESULT	1	PubMed
38710003	RESULT	2	PubMed

1 to 10 of 1,086

See all 1,086 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL1773

GET https://conductscience.org/api/drugs/v1/CHEMBL1773/diseases?page=2

API reference For AI assistants